Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study

Gynecologic Oncology
Dimitrios PectasidesSotirios A Raptis

Abstract

A prospective phase II study was conducted to evaluate the efficacy and toxicity of oxaliplatin plus 5-fluoruracil (5-FU) and high-dose leucovorin (LV) (FOLFOX-4) in patients with platinum-resistant, taxane-pretreated recurrent ovarian cancer. Thirty-eight patients, with a median age of 58 years (range 33-77), were treated with oxaliplatin 85 mg m(-2) as a 2-h infusion on day 1, LV 200 mg m(-2) day(-1) as a 2-h infusion followed by bolus 5-FU 400 mg m(-2) day(-1) and a 22-h infusion of 5-FU 600 mg m(-2) day(-1) for 2 consecutive days. Treatment was repeated every 3 weeks. Patients were evaluated for response every two cycles. The vast majority of patients had performance status 0 or 1 and 76.3% had > or = 2 metastatic sites. A median number of four cycles per patient (range, 1-8) were administered. Based on an intention-to-treat analysis, 3 patients (7.9%) achieved a complete response (CR) and 8 (21.1%) achieved a partial response (PR), for an overall response rate of 29%. Another 29% of patients had stable disease (SD). The median relapse-free survival was 5.2 months (range 2.5-17), the median time to tumor progression was 4.8 months (range 0.6-19), and the median overall survival was 10.1 months (range 0.2-36). Toxicity was m...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Nov 6, 1995·Cancer Letters·L PendyalaP J Creaven
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J PiccartE Cvitkovic
May 1, 1996·Gynecologic Oncology·M PréfontaineL Buley
Dec 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P CholletE Cvitkovic
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P SouliéE Cvitkovic
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F Maindrault-GoebelA de Gramont
Dec 21, 2000·Current Oncology Reports·A A Garcia
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L ZelekM Spielmann
Jun 14, 2002·International Journal of Oncology·A LatorreV Lorusso
Dec 13, 2002·American Journal of Clinical Oncology·Charalambos KouroussisVassilis Georgoulias
Mar 22, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PectasidesC Kosmas
May 20, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G CiucciG Bianchedi
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paula M FracassoJames S Hoffman
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Mar 7, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R E BoardG C Jayson
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergDaniel J Sargent

❮ Previous
Next ❯

Citations

Apr 25, 2013·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hee Jun LeeYong Sang Song
Jul 8, 2011·Cancer Management and Research·Gina M Mantia-SmaldoneAnda M Vlad
Oct 3, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S FuR C Bast
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P HarnettR Stuart-Harris
Jul 13, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M L HarrisonM E Gore
Nov 18, 2010·Archives of Gynecology and Obstetrics·Ansgar Brüning, Ioannis Mylonas
Sep 8, 2010·Seminars in Oncology·Abdalla SholiGloria J Morris
Mar 27, 2007·Cancer Treatment Reviews·Britta StordalRoss Davey
Apr 17, 2016·Critical Reviews in Oncology/hematology·Wen XuJermaine I G Coward
Aug 17, 2010·Chemico-biological Interactions·Huei-Fang LiuJui-I Chao
Aug 10, 2013·Journal of Experimental & Clinical Cancer Research : CR·Patrizia ViciLuigi Di Lauro
Mar 15, 2015·Endocrine-related Cancer·J HadouxE Baudin
Jan 23, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John HornbergerStephen Raab
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sheri L SpuntClinton F Stewart
May 12, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Karen SayalChristine Parkinson
Feb 3, 2016·F1000Research·Martin L AshdownBrendon J Coventry
Mar 20, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jonathan D BlackElena Ratner
Dec 17, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gregor SeligerHans-Joachim Schmoll
Nov 16, 2019·Expert Opinion on Investigational Drugs·Melita MoioliSimone Ferrero
Jan 23, 2020·Diagnostics·Abdulaziz Babaier, Prafull Ghatage
Oct 21, 2011·Journal of Clinical Pathology·Jay D NaikTimothy J Perren
Feb 18, 2021·Environmental Science and Pollution Research International·Madhuri GroverDhruv Setia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.